MeiraGTx Holdings plc Other Current Liabilities
MeiraGTx Holdings plc (MGTX) had Other Current Liabilities of $15.11 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:OtherLiabilitiesCurrent · last filed 2026-08-13
- 2026-06-30: Other Liabilities, Current $15.11M.
- 2026-03-31: Other Liabilities, Current $105.11M.
- 2025-12-31: Other Liabilities, Current $50.28M.
- 2025-09-30: Other Liabilities, Current $28.24M.
| Period end | Other Liabilities, Current | Other Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $15.11M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $105.11M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $50.28M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $28.24M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $6.81M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $580.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $903.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $1.28M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $970.00K 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $1.01M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $1.28M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $2.48M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $2.23M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $2.57M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $6.63M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $3.36M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $983.00K 10-Q · filed 2022-08-11 | |
| 2020-12-31 | $24.00K 10-K · filed 2022-03-10 | $24.45K 10-K · filed 2021-03-11 |
| 2020-09-30 | $17.64K 10-Q · filed 2020-11-05 | |
| 2020-03-31 | $60.78K 10-Q · filed 2020-05-07 | |
| 2019-03-31 | $195.62K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $437.05K 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |